(Press-News.org) This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform, similar to the preclinical stage KAT6 inhibitor (MEN2312) licensed a year ago and which advanced rapidly into the clinical phase.
Under the agreement, Menarini Group will be granted global rights to develop and commercialize the asset. The deal includes a $20m upfront payment, and the combined value, including all development, regulatory, and commercial milestones, is over $550 million, followed by tiered royalties.
FLORENCE, Italy and CAMBRIDGE, Mass., January 10, 2025 : The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, and Insilico Medicine (“Insilico”), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the companies have entered into an exclusive licensing agreement granting Stemline the global rights to develop and commercialize a preclinical small molecule targeting high unmet needs in oncology.
The asset is a highly selective and potentially best-in-class small molecule inhibitor targeting a broad range of solid tumor cancers, developed with the help of Chemistry42, Insilico’s generative chemistry engine, and Insilico’s drug discovery team. The asset has successfully completed preclinical development and has demonstrated broad anti-tumor activity in selected cancers.
“We are thrilled to enter our second collaboration with Insilico Medicine, a leader in the field of generative AI, for a highly selective and potentially best-in-class small molecule targeting a broad range of cancers,” said Elcin Barker Ergun, CEO of the Menarini Group. “This asset will help us enter into new areas of high unmet need, expanding the tumor areas where we can help cancer patients with ground-breaking therapies.”
“Our previous experience with Menarini Stemline proved that the company is efficient, agile, strategic, and committed to rapidly delivering the best novel therapeutic solutions to patients with cancer, maximizing the probability of success of the program,” said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. “Menarini Stemline’s strategic visionary management is rapidly re-shaping the field of oncology, and we are very happy to take part in their quest to extend patients’ lives around the world.”
Under the terms of the agreement, Stemline will provide a $20 million upfront payment to Insilico. The combined value of the deal, including all development, regulatory, and commercial milestones, is over $550 million, followed by tiered royalties.
Prior to this collaboration, the Menarini Group and Insilico entered an exclusive licensing agreement in January 2024 for MEN2312, an innovative small molecule for breast cancer treatment and other oncology indications.
About MEN2312
MEN2312 was designed by Insilico’s R&D team with the help of its end-to-end Pharma Generative AI platform to inhibit KAT6 and block endocrine receptor (ER) at the transcriptional level, giving it the potential to overcome resistance to endocrine therapies due to mutation or ligand-independent constitutive activation of ER. In preclinical studies, the molecule has demonstrated potent inhibition against KAT6 in multiple CDX and PDX models with good efficacy and safety.
About The Menarini Group
The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of over $4.7 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia. With 18 production sites and 9 Research and Development centers, Menarini's products are available in 140 countries worldwide. For further information, please visit menarini.com.
About Stemline Therapeutics Inc.
Stemline Therapeutics, Inc. ("Stemline") a wholly-owned subsidiary of the Menarini Group, is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. Stemline commercializes ORSERDU® (elacestrant) in the U.S. and in the E.U., an oral endocrine therapy indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Stemline also commercializes ELZONRIS® (tagraxofusp-erzs), a novel targeted treatment directed to CD123 for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic cancer, in the United States and Europe, which is the only approved treatment for BPDCN in the US and EU to date. Stemline also commercializes NEXPOVIO® (selinexor) in Europe, an XPO1 inhibitor for multiple myeloma. Stemline also has an extensive clinical pipeline of small molecules and biologics in various stages of development for a host of solid and hematologic cancers.
About Insilico Medicine
Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com
Media Contacts
The Menarini Group
Valeria Speroni Cardi
Email: pressoffice@menarini.com
Stemline Therapeutics, Inc.
Cheya Pope
Email: media@menarinistemline.com
Insilico Medicine
Joy Hu
Email: media@insilico.com
END
Agriculture accounts for 8 percent of all greenhouse gas (GHG) emissions in Germany. “However, emissions within this sector, could be reduced by 22.5 percent or over 15 million tonnes of GHG annually, if the social cost of carbon were reflected in food prices,” says Julian Schaper, guest scientist at PIK and lead author of the study published in the journal Food Policy. In the Federal Climate Change Act passed in 2019, the government set itself the goal of reducing annual emissions from the current 62 million tonnes to 56 Mt GHG by 2030.
The social cost of carbon is an estimate of the economic damages that would result from emitting one additional tonne of carbon into the ...
Fukuoka, Japan—Researchers at Kyushu University have developed a device that combines a catalyst and microwave flow reaction to efficiently convert complex polysaccharides into simple monosaccharides. The device utilizes a continuous-flow hydrolysis process, where cellobiose—a disaccharide made from two glucose molecules—is passed through a sulfonated carbon catalyst that is heated using microwaves. The subsequent chemical reaction breaks down cellobiose into glucose. Their results were published in the journal ACS Sustainable Chemistry & Engineering.
Converting biomass into ...
A recent study has uncovered the essential roles of two proteoglycans, biglycan and decorin, in maintaining bone mass, water retention, and bulk/in situ mechanical competence. Through the use of genetically modified mouse models, the research demonstrates that while biglycan plays a predominant role in preserving bone structure and toughness, decorin significantly contributes to the bone’s mechanical properties. These findings reveal how these proteins interact with water and other matrix components to regulate the mechanical ...
Researchers Ibuki Taniuchi, Ryota Akiyama, Rei Hobara, and Shuji Hasegawa of the University of Tokyo have demonstrated that the direction of the spin-polarized current can be restricted to only one direction in a single-atom layer of a thallium-lead alloys when irradiated at room temperature. The discovery defies conventions: single-atom layers have been thought to be almost completely transparent, in other words, negligibly absorbing or interacting with light. The one-directional flow of the current observed in this study makes possible functionality beyond ...
A team led by researchers at the University of Tokyo have created a dataset of the whole atmosphere, enabling new research to be conducted on previously difficult-to-study regions. Using a new data-assimilation system called JAGUAR-DAS, which combines numerical modeling with observational data, the team created a nearly 20-yearlong set of data spanning multiple levels of the atmosphere from ground level up to the lower edges of space. Being able to study the interactions of these layers vertically and around the globe could improve climate modeling and seasonal weather forecasting. There is also potential for interdisciplinary research between atmospheric scientists ...
PITTSBURGH, Jan. 10, 2025 – A self-destructing vaccine administered intravenously provides additional safety and protection against tuberculosis (TB) in macaque monkeys, suggests new University of Pittsburgh research published today in Nature Microbiology.
The in-built safety mechanisms circumvent the possibility of an accidental self-infection with weakened mycobacteria, offering a safe and effective way to combat the disease that was named as the deadliest of 2024 by the World Health Organization.
“Although the idea of intravenous vaccination with a live vaccine may sound scary, it was very ...
The group of bacteria called Enterobacteriaceae, including Klebsiella pneumoniae, Shigella, E.coli and others, is present at low levels as part of a healthy human gut microbiome. But at high levels - caused for example by increased inflammation in the body, or by eating contaminated food - these bugs can cause illness and disease. In extreme cases, too much Enterobacteriaceae in the gut can be life-threatening.
Researchers have used computational approaches including AI to analyse the gut microbiome composition of over 12,000 people across 45 countries from their stool samples. They found that a person’s microbiome ‘signature’ can predict ...
Whether it’s the meeting room of an office building, the exhibition room of a museum or the waiting area of a government office, many people gather in such places, and quickly the air becomes thick. This is partly due to the increased humidity. Ventilation systems are commonly used in office and administrative buildings to dehumidify rooms and ensure a comfortable atmosphere. Mechanical dehumidification works reliably, but it costs energy and – depending on the electricity used – has a negative climate impact.
Against this backdrop, a team of researchers from ETH Zurich investigated a new approach to passive dehumidification of indoor spaces. Passive, in this context, means ...
More than half of 23-year-olds in a European study show restrictive, emotional or uncontrolled eating behaviours, according to new research led by the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London. Structural brain differences appear to play a role in the development of these eating habits.
The study, published in Nature Mental Health, investigates the links between genetics, brain structure and disordered eating behaviours in young people. Researchers found that the process of ‘brain maturation’, ...
A research team led by Prof. QIN Guozheng from the Institute of Botany of the Chinese Academy of Sciences has unveiled a previously unrecognized mechanism by which the RNA N6–methyladenosine (m6A) demethylase SlALKBH2 undergoes reduction-oxidation (redox) modification. This alteration affects its stability and its physiological role in regulating the normal ripening of tomato fruits.
In this study, published in Nature Plants, the researchers deepened their understanding of the role of hydrogen peroxide ...
